The efficacy of the addition of prokinetics to antibiotics in the treatment of patients with small intestinal bacterial overgrowth: A prospective, randomized, double-blind clinical trial

The efficacy of the addition of trimebutine maleate to rifaximin in the treatment of patients with small intestinal bacterial overgrowth: A prospective, randomized, double-blind clinical trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0004836

Enrollment

Registered

2020-03-17

Start date

2020-03-23

Completion date

Unknown

Last updated

2020-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : In the control group, two placebo tablets and rifaxmin 400mg are taken three times a day for every 8 hours, and the experimental group take trmebutine maleate 200mg and rifaximin 400mg three ti

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with gastrointestinal disorders such as functional dyspepsia, bloating, loose stool, and diarrhea, who were diagnosed with small intestinal bacterial overgrowth by positive glucose breath test

Exclusion criteria

Exclusion criteria: 1. Patients who are taking a gastric acid secretion inhibitor 2. Patients who have taken antibiotics within three months 3. Patients whose have diagnosed with recurred cancer, stenosis, or organic obstruction by endoscopy or upper gastrointestinal series 4. Patients who have undergone gastrointestinal surgery other than stomach surgery (except appendectomy) 5. Within the last 15 days, a disease or lesion, which could affect the motor function, has been found to be associated with gastrointestinal symptoms (gastric ulcer, duodenal ulcer, esophageal cancer, enteritis, colitis, etc.) 6. Patients who have a disease that has a signifincant impact on this study (e.g. creatinine > 3.0mg/dl, severe liver disease) 7. Patients who are taking drugs that may affect the gastrointestinal function evaluation, such as narcotics, probiotics, and anti-diarrheal medications (except those who have more than seven days of rest). 8. Pregnany and breast feeding 9. Patients unfit for this study

Design outcomes

Primary

Measure	Time frame
Negative rate of glucose breath test	—

Secondary

Measure	Time frame
Symptom improvement rate	—

Countries

Korea, Republic of

Contacts

Public ContactDae Bum Kim

The Catholic University of Korea, St. Vincent's Hospital

Outcome results